# Staccato Loxapine Single Dose PK

> **NCT00444028** · PHASE1 · COMPLETED · sponsor: **Alexza Pharmaceuticals, Inc.** · enrollment: 50 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** inhaled Loxapine 0.625 mg
- **DRUG:** inhaled Loxapine 1.25 mg
- **DRUG:** inhaled Loxapine 2.5 mg
- **DRUG:** inhaled Loxapine 5 mg
- **DRUG:** inhaled Loxapine 10 mg
- **DRUG:** inhaled Placebo (0 mg)

## Key facts

- **NCT ID:** NCT00444028
- **Lead sponsor:** Alexza Pharmaceuticals, Inc.
- **Sponsor class:** UNKNOWN
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00444028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00444028, "Staccato Loxapine Single Dose PK". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00444028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*